Claris Lifesciences Limited - India

 

 
Claris appears as case study at ISB
ISBites learn from pharma company
Claris Lifesciences and Xcelris Labs files a joint patent in Biotherapic Protein
Claris Lifesciences launches Olympiad '08
Modern Pharmaceutical
Fitch tracks Claris' rising growth story.
Gearing up for growth
Claris forays into the sunrise area biotechnology.
Marching ahead
Beena Handa, on storming her way through male bastion


Marching ahead

NEW DELHI: Claris Life sciences on Tuesday said it has received US food and drug administration (USFDA) nod for selling three different injectable products in the US market.

Ahmedabad-based company has got the approval from USFDA for selling Ciproflaxacin and Metronidazole, the anti infective compounds and Ondansetron, an anti vomiting drug in the US market.

The successful launch of these products in the market would provide a major fillip to the company's US strategy and overall business growth, the company said in a statement.

"After USFDA acceptance of our facility, this is perhaps one of the most important milestones, we have achieved as far as US operation of the company," Mr Arjun Handa, COO of Claris said.

Claris is an international Life science company operating in critical care segment, with special focus on injectables. - PTI

- April 2008

 

Claris Lifesciences Ltd. All Rights Reserved.  :: Terms of Use  ::Privacy Policy